Pages that link to "Q54018637"
Jump to navigation
Jump to search
The following pages link to Rapid suppression of hematopoiesis by standard or pegylated interferon-alpha. (Q54018637):
Displaying 50 items.
- Antiviral therapy in hepatitis C virus cirrhotic patients in compensated and decompensated condition (Q27490340) (← links)
- The Use of Thrombopoietin Receptor Agonists for Correction of Thrombocytopenia prior to Elective Procedures in Chronic Liver Diseases: Review of Current Evidence (Q28074484) (← links)
- Complementary treatments of chronic viral hepatitis C (Q33370676) (← links)
- Erythropoietin treatment is associated with more severe thrombocytopenia in patients with chronic hepatitis C undergoing antiviral therapy (Q33372925) (← links)
- Platelet autoantibodies are common in hepatitis C infection, irrespective of the presence of thrombocytopenia (Q33372989) (← links)
- Bone marrow toxicity in HCV genotype 5a-infected patient after peg-IFN alpha-2a and ribavirin therapy (Q33382114) (← links)
- Use of hematopoietic growth factor in the management of hematological side effects associated to antiviral treatment for HCV hepatitis (Q33394544) (← links)
- Peripheral blood cytopaenia limiting initiation of treatment in chronic hepatitis C patients otherwise eligible for antiviral therapy (Q33400529) (← links)
- Mechanism of thrombocytopenia in chronic hepatitis C as evaluated by the immature platelet fraction (Q33401841) (← links)
- Incidence and predictors of hematological side effects in chronic HCV Egyptian patients treated with PEGylated interferon and ribavirin (Q33408043) (← links)
- Management of Thrombocytopenia in Chronic Liver Disease: Focus on Pharmacotherapeutic Strategies (Q33427048) (← links)
- From chronic immune thrombocytopenia to severe aplastic anemia: recent insights into the evolution of eltrombopag. (Q33441627) (← links)
- Pegylated-interferon-α(2a) in clinical practice: how to manage patients suffering from side effects (Q34164776) (← links)
- Erythropoietin rs1617640 G allele associates with an attenuated rise of serum erythropoietin and a marked decline of hemoglobin in hepatitis C patients undergoing antiviral therapy (Q34246440) (← links)
- Management of Hepatitis C Antiviral Therapy Adverse Effects (Q34538771) (← links)
- Side effects of therapy of hepatitis C and their management (Q34984142) (← links)
- The practical management of treatment failure in chronic hepatitis C: a summary of current research and management options for refractory patients (Q34996746) (← links)
- Side effects of therapy for chronic hepatitis C. (Q35133495) (← links)
- Suppression of haematopoiesis during therapy of chronic hepatitis C with different interferon alpha mono and combination therapy regimens (Q35597625) (← links)
- Controversies in the management of hepatitis C patients with advanced fibrosis and cirrhosis. (Q35689601) (← links)
- Histologic and Immunohistochemical Features of the Skin Lesions in CANDLE Syndrome (Q35764807) (← links)
- Peginterferon alfa-2a: a review of approved and investigational uses (Q35874153) (← links)
- Peginterferon-alpha 2a (40 kDa)/ribavirin combination for the treatment of chronic hepatitis C infection (Q35917238) (← links)
- The management of side-effects during therapy for hepatitis C. (Q35936934) (← links)
- Once-daily dose regimen of ribavirin is interchangeable with a twice-daily dose regimen: randomized open clinical trial (Q36120739) (← links)
- Epoetin alfa for the treatment of combination therapy-induced hemolytic anemia in patients infected with hepatitis C virus (Q36146443) (← links)
- Anti-inflammatory properties of Type I interferons (Q36454474) (← links)
- Anemia management in the era of triple combination therapy for chronic HCV. (Q36496953) (← links)
- Modeling Ribavirin-Induced Anemia in Patients with Chronic Hepatitis C Virus (Q36600070) (← links)
- Management complexities of HIV/hepatitis C virus coinfection in the twenty-first century (Q36995854) (← links)
- Association of host pharmacodynamic effects with virologic response to pegylated interferon alfa-2a/ribavirin in chronic hepatitis C (Q37064110) (← links)
- Does a rapid decline in the hematological and biochemical parameters induced by interferon and ribavirin combination therapy for the hepatitis C virus predict a sustained viral response? (Q37136576) (← links)
- Critical review of the use of erythropoietin in the treatment of anaemia during therapy for chronic hepatitis C. (Q37975253) (← links)
- Safety of direct-acting antivirals in the treatment of chronic hepatitis C. (Q38189110) (← links)
- Type I interferon as a biomarker in autoimmunity and viral infection: a leukocyte subset-specific analysis unveils hidden diagnostic options (Q38867891) (← links)
- Peg-IFN and ribavirin treatment for recurrence of genotype 2 and 3 hepatitis C after liver transplantation (Q41504212) (← links)
- Role of hematopoietic growth factors as adjuncts in the treatment of chronic hepatitis C patients (Q41860936) (← links)
- Pure red cell aplasia caused by pegylated interferon-α-2a plus ribavirin in the treatment of chronic hepatitis C (Q41874865) (← links)
- Anti-Erythropoietin Antibody Associated Pure Red Cell Aplasia Resolved after Liver Transplantation (Q42239843) (← links)
- T cell receptor excision circles (TRECs), CD4+, CD8+, and their CD45RO+, and CD45RA+, subpopulations in hepatitis C virus (HCV)-HIV-co-infected patients during treatment with interferon alpha plus ribavirin: analysis in a population on effective ant (Q42502604) (← links)
- Epoetin alpha improves the response to antiviral treatment in HCV-related chronic hepatitis (Q42998759) (← links)
- Cost-effectiveness of hematologic growth factors for anemia occurring during hepatitis C combination therapy (Q43034061) (← links)
- Changes in haemoglobin during interferon alpha-2b plus ribavirin combination therapy for chronic hepatitis C virus infection. (Q43586612) (← links)
- Pegylated-interferon induced severe bone marrow hypoplasia in a patient with multiple myeloma receiving thalidomide (Q44667235) (← links)
- Antibody-mediated pure red cell aplasia due to epoetin alfa during antiviral therapy of chronic hepatitis C. (Q44911029) (← links)
- Erythropoietic response to anemia in chronic hepatitis C patients receiving combination pegylated interferon/ribavirin (Q44989619) (← links)
- Risk factors for anaemia in human immunodeficiency virus/hepatitis C virus-coinfected patients treated with interferon plus ribavirin (Q45401217) (← links)
- Ribavirin levels and haemoglobin decline in early virological responders and non-responders to hepatitis C virus combination therapy (Q45420864) (← links)
- Gene expression profiles associated with anaemia and ITPA genotypes in patients with chronic hepatitis C (CH‐C) (Q46902016) (← links)
- Clinical Evaluation of Terap C Vaccine in Combined Treatment with Interferon and Ribavirin in Patients with Hepatitis C. (Q47108259) (← links)